Industry Research Reports

Home > Reports > Service & Software > Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2032

Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2032

Industry: Service & Software

Published Date: 2026-01-14

Pages: 132 Pages

Report ld: 5649946

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Lung Cancer Screening Software Market Size(US$)

CAGR 2026-2032

18.0%

Market Size,2032

USD 5,434

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 2,013 million

Market Forecast in 2032(Value)

US$ 5,434 million

CAGR

18.0%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Lung Cancer Screening Software market is projected to grow from US$ 1706 million in 2025 to US$ 5434 million by 2032, at a CAGR of 18.0% (2026-2032), driven by critical product segments and diverse end‑use applications.

Lung cancer screening software is medical software based on medical imaging (primarily low-dose CT) and algorithm models. It is used to automatically detect lung nodules, analyze morphological characteristics, assess malignancy risk, and assist in follow-up management. Its goal is to improve the early detection rate of lung cancer, reduce the missed diagnosis rate, and support clinical decision-making and population screening.

Upstream components mainly include medical imaging data sources (CT equipment, imaging centers), computing power and cloud infrastructure, algorithm frameworks, and data annotation resources. Downstream components primarily target hospital radiology departments, regional public health screening projects, physical examination institutions, and health management and insurance-related service scenarios.

Global Market Future Development Trends

With the increasing incidence of lung cancer and the aging population, low-dose CT screening is being included in recommended or pilot programs in more and more countries. Traditional manual image interpretation is insufficient to support large-scale screening, making efficient and replicable software solutions a necessity and driving the rapid deployment of lung cancer screening software in hospitals and regional population screening.

The market is evolving from single nodule detection to risk stratification, follow-up comparison, multi-temporal analysis, and automated reporting. Algorithm stability, cross-device generalization ability, and clinical interpretability have become core competitive advantages, elevating the value of software from an "auxiliary tool" to a "key node in the screening process."

Against increasingly stringent regulatory requirements from the FDA, CE, and NMPA, compliance certification has become a market entry barrier. In the future, software will increasingly take the form of platforms, integrating with PACS, regional screening systems, and cloud services, transforming from single-point sales to long-term service revenue through subscription or pay-per-view models.

Report Includes:

This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Lung Cancer Screening Software market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Siemens Healthineers
GE HealthCare
Philips Healthcare
Canon Medical Systems
United Imaging Healthcare
InferVision
Airdoc
VUNO
Lunit
Qure.ai
Riverain Technologies
Zebra Medical Vision
Arterys
Deepwise
EverFortune AI

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Cloud-Based
Web-Based

Segment by Application

Hospitals
Medical Examination Institutions
Public Health Screening
Others

Segment by Category

Nodule Detection
Nodule Analysis
Full-Process Screening
Predictive Assessment

Segment by Division

Standalone AI Software
PACS/RIS Integrated Plugin
Built-in Solution for Imaging Equipment
Regional Screening Platform System

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Lung Cancer Screening Software study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential

Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves

Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application

Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers

Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers

Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas

Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges

Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles

Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments

Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels

Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 14: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Lung Cancer Screening Software: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Lung Cancer Screening Software Market Size by Type, 2021 vs 2025 vs 2032

1.2.2 Cloud-Based

1.2.3 Web-Based

1.3 Market Segmentation by Screening Technologies

1.3.1 Global Lung Cancer Screening Software Market Size by Screening Technologies, 2021 vs 2025 vs 2032

1.3.2 Nodule Detection

1.3.3 Nodule Analysis

1.3.4 Full-Process Screening

1.3.5 Predictive Assessment

1.4 Market Segmentation by System Integration Level

1.4.1 Global Lung Cancer Screening Software Market Size by System Integration Level, 2021 vs 2025 vs 2032

1.4.2 Standalone AI Software

1.4.3 PACS/RIS Integrated Plugin

1.4.4 Built-in Solution for Imaging Equipment

1.4.5 Regional Screening Platform System

1.5 Market Segmentation by Application

1.5.1 Global Lung Cancer Screening Software Market Size by Application, 2021 vs 2025 vs 2032

1.5.2 Hospitals

1.5.3 Medical Examination Institutions

1.5.4 Public Health Screening

1.5.5 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Executive Summary

2.1 Global Lung Cancer Screening Software Revenue Estimates and Forecasts (2021-2032)

2.2 Global Lung Cancer Screening Software Revenue by Region

2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032

2.2.2 Historical and Forecasted Revenue by Region (2021-2032)

2.2.3 Global Revenue-Based Market Share by Region (2021-2032)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape

3.1 Global Lung Cancer Screening Software Players’ Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2021-2026)

3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Players (2021 vs 2025)

3.2 Global Lung Cancer Screening Software Companies Headquarters and Service Footprint

3.3 Key Player Market Share by Product Type

3.3.1 Cloud-Based: Market Share by Key Players

3.3.2 Web-Based: Market Share by Key Players

3.4 Global Lung Cancer Screening Software Market Concentration and Dynamics

3.4.1 Global Market Concentration

3.4.2 Market Entry and Exit Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation

4.1 Global Lung Cancer Screening Software Market by Type

4.1.1 Global Revenue by Type (2021-2032)

4.1.2 Global Revenue-Based Market Share by Type (2021-2032)

4.2 Global Lung Cancer Screening Software Market by Screening Technologies

4.2.1 Global Revenue by Screening Technologies (2021-2032)

4.2.2 Global Revenue-Based Market Share by Screening Technologies (2021-2032)

4.3 Global Lung Cancer Screening Software Market by System Integration Level

4.3.1 Global Revenue by System Integration Level (2021-2032)

4.3.2 Global Revenue-Based Market Share by System Integration Level (2021-2032)

4.4 Key Product Attributes and Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Downstream Applications and Customers

5.1 Global Lung Cancer Screening Software Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)

5.1.2 Revenue-Based Market Share by Application (2021-2032)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2021-2032)

6.2 North America Key Players’ Revenue in 2025

6.3 North America Lung Cancer Screening Software Market Size by Application (2021-2032)

6.4 North America Growth Accelerators and Market Barriers

6.5 North America Lung Cancer Screening Software Market Size by Country

6.5.1 North America Revenue Trends by Country

6.5.2 US

6.5.3 Canada

6.5.4 Mexico

7 Europe

7.1 Europe Market Size (2021-2032)

7.2 Europe Key Players’ Revenue in 2025

7.3 Europe Lung Cancer Screening Software Market Size by Application (2021-2032)

7.4 Europe Growth Accelerators and Market Barriers

7.5 Europe Lung Cancer Screening Software Market Size by Country

7.5.1 Europe Revenue Trends by Country

7.5.2 Germany

7.5.3 France

7.5.4 U.K.

7.5.5 Italy

7.5.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2021-2032)

8.2 Asia-Pacific Key Players’ Revenue in 2025

8.3 Asia-Pacific Lung Cancer Screening Software Market Size by Application (2021-2032)

8.4 Asia-Pacific Growth Accelerators and Market Barriers

8.5 Asia-Pacific Lung Cancer Screening Software Market Size by Region

8.5.1 Asia-Pacific Revenue Trends by Region

8.6 China

8.7 Japan

8.8 South Korea

8.9 Australia

8.10 India

8.11 Southeast Asia

8.11.1 Indonesia

8.11.2 Vietnam

8.11.3 Malaysia

8.11.4 Philippines

8.11.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2021-2032)

9.2 Central and South America Key Players’ Revenue in 2025

9.3 Central and South America Lung Cancer Screening Software Market Size by Application (2021-2032)

9.4 Central and South America Investment Opportunities and Key Challenges

9.5 Central and South America Lung Cancer Screening Software Market Size by Country

9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)

9.5.2 Brazil

9.5.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2021-2032)

10.2 Middle East and Africa Key Players’ Revenue in 2025

10.3 Middle East and Africa Lung Cancer Screening Software Market Size by Application (2021-2032)

10.4 Middle East and Africa Investment Opportunities and Key Challenges

10.5 Middle East and Africa Lung Cancer Screening Software Market Size by Country

10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)

10.5.2 GCC Countries

10.5.3 Israel

10.5.4 Egypt

10.5.5 South Africa

11 Corporate Profile

11.1 Siemens Healthineers

11.1.1 Siemens Healthineers Corporation Information

11.1.2 Siemens Healthineers Business Overview

11.1.3 Siemens Healthineers Lung Cancer Screening Software Product Features and Attributes

11.1.4 Siemens Healthineers Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.1.5 Siemens Healthineers Lung Cancer Screening Software Revenue by Product in 2025

11.1.6 Siemens Healthineers Lung Cancer Screening Software Revenue by Application in 2025

11.1.7 Siemens Healthineers Lung Cancer Screening Software Revenue by Geographic Area in 2025

11.1.8 Siemens Healthineers Lung Cancer Screening Software SWOT Analysis

11.1.9 Siemens Healthineers Recent Developments

11.2 GE HealthCare

11.2.1 GE HealthCare Corporation Information

11.2.2 GE HealthCare Business Overview

11.2.3 GE HealthCare Lung Cancer Screening Software Product Features and Attributes

11.2.4 GE HealthCare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.2.5 GE HealthCare Lung Cancer Screening Software Revenue by Product in 2025

11.2.6 GE HealthCare Lung Cancer Screening Software Revenue by Application in 2025

11.2.7 GE HealthCare Lung Cancer Screening Software Revenue by Geographic Area in 2025

11.2.8 GE HealthCare Lung Cancer Screening Software SWOT Analysis

11.2.9 GE HealthCare Recent Developments

11.3 Philips Healthcare

11.3.1 Philips Healthcare Corporation Information

11.3.2 Philips Healthcare Business Overview

11.3.3 Philips Healthcare Lung Cancer Screening Software Product Features and Attributes

11.3.4 Philips Healthcare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.3.5 Philips Healthcare Lung Cancer Screening Software Revenue by Product in 2025

11.3.6 Philips Healthcare Lung Cancer Screening Software Revenue by Application in 2025

11.3.7 Philips Healthcare Lung Cancer Screening Software Revenue by Geographic Area in 2025

11.3.8 Philips Healthcare Lung Cancer Screening Software SWOT Analysis

11.3.9 Philips Healthcare Recent Developments

11.4 Canon Medical Systems

11.4.1 Canon Medical Systems Corporation Information

11.4.2 Canon Medical Systems Business Overview

11.4.3 Canon Medical Systems Lung Cancer Screening Software Product Features and Attributes

11.4.4 Canon Medical Systems Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.4.5 Canon Medical Systems Lung Cancer Screening Software Revenue by Product in 2025

11.4.6 Canon Medical Systems Lung Cancer Screening Software Revenue by Application in 2025

11.4.7 Canon Medical Systems Lung Cancer Screening Software Revenue by Geographic Area in 2025

11.4.8 Canon Medical Systems Lung Cancer Screening Software SWOT Analysis

11.4.9 Canon Medical Systems Recent Developments

11.5 United Imaging Healthcare

11.5.1 United Imaging Healthcare Corporation Information

11.5.2 United Imaging Healthcare Business Overview

11.5.3 United Imaging Healthcare Lung Cancer Screening Software Product Features and Attributes

11.5.4 United Imaging Healthcare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.5.5 United Imaging Healthcare Lung Cancer Screening Software Revenue by Product in 2025

11.5.6 United Imaging Healthcare Lung Cancer Screening Software Revenue by Application in 2025

11.5.7 United Imaging Healthcare Lung Cancer Screening Software Revenue by Geographic Area in 2025

11.5.8 United Imaging Healthcare Lung Cancer Screening Software SWOT Analysis

11.5.9 United Imaging Healthcare Recent Developments

11.6 InferVision

11.6.1 InferVision Corporation Information

11.6.2 InferVision Business Overview

11.6.3 InferVision Lung Cancer Screening Software Product Features and Attributes

11.6.4 InferVision Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.6.5 InferVision Recent Developments

11.7 Airdoc

11.7.1 Airdoc Corporation Information

11.7.2 Airdoc Business Overview

11.7.3 Airdoc Lung Cancer Screening Software Product Features and Attributes

11.7.4 Airdoc Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.7.5 Airdoc Recent Developments

11.8 VUNO

11.8.1 VUNO Corporation Information

11.8.2 VUNO Business Overview

11.8.3 VUNO Lung Cancer Screening Software Product Features and Attributes

11.8.4 VUNO Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.8.5 VUNO Recent Developments

11.9 Lunit

11.9.1 Lunit Corporation Information

11.9.2 Lunit Business Overview

11.9.3 Lunit Lung Cancer Screening Software Product Features and Attributes

11.9.4 Lunit Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.9.5 Lunit Recent Developments

11.10 Qure.ai

11.10.1 Qure.ai Corporation Information

11.10.2 Qure.ai Business Overview

11.10.3 Qure.ai Lung Cancer Screening Software Product Features and Attributes

11.10.4 Qure.ai Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.10.5 Company Ten Recent Developments

11.11 Riverain Technologies

11.11.1 Riverain Technologies Corporation Information

11.11.2 Riverain Technologies Business Overview

11.11.3 Riverain Technologies Lung Cancer Screening Software Product Features and Attributes

11.11.4 Riverain Technologies Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.11.5 Riverain Technologies Recent Developments

11.12 Zebra Medical Vision

11.12.1 Zebra Medical Vision Corporation Information

11.12.2 Zebra Medical Vision Business Overview

11.12.3 Zebra Medical Vision Lung Cancer Screening Software Product Features and Attributes

11.12.4 Zebra Medical Vision Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.12.5 Zebra Medical Vision Recent Developments

11.13 Arterys

11.13.1 Arterys Corporation Information

11.13.2 Arterys Business Overview

11.13.3 Arterys Lung Cancer Screening Software Product Features and Attributes

11.13.4 Arterys Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.13.5 Arterys Recent Developments

11.14 Deepwise

11.14.1 Deepwise Corporation Information

11.14.2 Deepwise Business Overview

11.14.3 Deepwise Lung Cancer Screening Software Product Features and Attributes

11.14.4 Deepwise Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.14.5 Deepwise Recent Developments

11.15 EverFortune AI

11.15.1 EverFortune AI Corporation Information

11.15.2 EverFortune AI Business Overview

11.15.3 EverFortune AI Lung Cancer Screening Software Product Features and Attributes

11.15.4 EverFortune AI Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)

11.15.5 EverFortune AI Recent Developments

12 Lung Cancer Screening Software Value Chain and Ecosystem Analysis

12.1 Lung Cancer Screening Software Value Chain (Ecosystem Structure)

12.2 Upstream Analysis

12.2.1 Key Technologies, Platforms and Infrastructure

12.3 Midstream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Lung Cancer Screening Software Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Lung Cancer Screening Software Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Lung Cancer Screening Software Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 2. Global Lung Cancer Screening Software Market Size Growth Rate by Screening Technologies, 2021 vs 2025 vs 2032 (US$ Million)

Table 3. Global Lung Cancer Screening Software Market Size Growth Rate by System Integration Level, 2021 vs 2025 vs 2032 (US$ Million)

Table 4. Global Lung Cancer Screening Software Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Table 5. Global Lung Cancer Screening Software Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 6. Global Lung Cancer Screening Software Revenue by Region (US$ Million), 2021-2026

Table 7. Global Lung Cancer Screening Software Revenue by Region (US$ Million), 2027-2032

Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 9. Global Lung Cancer Screening Software Revenue by Players (US$ Million), 2021-2026

Table 10. Global Lung Cancer Screening Software Revenue-Based Market Share by Players (2021-2026)

Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)

Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Lung Cancer Screening Software Revenue, 2025

Table 13. Global Lung Cancer Screening Software Average Gross Margin (%) by Player (2021 vs 2025)

Table 14. Global Lung Cancer Screening Software Companies Headquarters

Table 15. Global Lung Cancer Screening Software Market Concentration Ratio (CR5)

Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis

Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 18. Global Lung Cancer Screening Software Revenue by Type (US$ Million), 2021-2026

Table 19. Global Lung Cancer Screening Software Revenue by Type (US$ Million), 2027-2032

Table 20. Global Lung Cancer Screening Software Revenue by Screening Technologies (US$ Million), 2021-2026

Table 21. Global Lung Cancer Screening Software Revenue by Screening Technologies (US$ Million), 2027-2032

Table 22. Global Lung Cancer Screening Software Revenue by System Integration Level (US$ Million), 2021-2026

Table 23. Global Lung Cancer Screening Software Revenue by System Integration Level (US$ Million), 2027-2032

Table 24. Key Product Attributes and Differentiation

Table 25. Global Lung Cancer Screening Software Revenue by Application (US$ Million), 2021-2026

Table 26. Global Lung Cancer Screening Software Revenue by Application (US$ Million), 2027-2032

Table 27. Lung Cancer Screening Software High-Growth Sectors Demand CAGR (2026-2032)

Table 28. Top Customers by Region

Table 29. Top Customers by Application

Table 30. North America Lung Cancer Screening Software Growth Accelerators and Market Barriers

Table 31. North America Lung Cancer Screening Software Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 32. Europe Lung Cancer Screening Software Growth Accelerators and Market Barriers

Table 33. Europe Lung Cancer Screening Software Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 34. Asia-Pacific Lung Cancer Screening Software Growth Accelerators and Market Barriers

Table 35. Asia-Pacific Lung Cancer Screening Software Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Central and South America Lung Cancer Screening Software Investment Opportunities and Key Challenges

Table 37. Central and South America Lung Cancer Screening Software Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 38. Middle East and Africa Lung Cancer Screening Software Investment Opportunities and Key Challenges

Table 39. Middle East and Africa Lung Cancer Screening Software Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 40. Siemens Healthineers Corporation Information

Table 41. Siemens Healthineers Description and Major Businesses

Table 42. Siemens Healthineers Product Features and Attributes

Table 43. Siemens Healthineers Revenue (US$ Million) and Gross Margin (2021-2026)

Table 44. Siemens Healthineers Revenue Proportion by Product in 2025

Table 45. Siemens Healthineers Revenue Proportion by Application in 2025

Table 46. Siemens Healthineers Revenue Proportion by Geographic Area in 2025

Table 47. Siemens Healthineers Lung Cancer Screening Software SWOT Analysis

Table 48. Siemens Healthineers Recent Developments

Table 49. GE HealthCare Corporation Information

Table 50. GE HealthCare Description and Major Businesses

Table 51. GE HealthCare Product Features and Attributes

Table 52. GE HealthCare Revenue (US$ Million) and Gross Margin (2021-2026)

Table 53. GE HealthCare Revenue Proportion by Product in 2025

Table 54. GE HealthCare Revenue Proportion by Application in 2025

Table 55. GE HealthCare Revenue Proportion by Geographic Area in 2025

Table 56. GE HealthCare Lung Cancer Screening Software SWOT Analysis

Table 57. GE HealthCare Recent Developments

Table 58. Philips Healthcare Corporation Information

Table 59. Philips Healthcare Description and Major Businesses

Table 60. Philips Healthcare Product Features and Attributes

Table 61. Philips Healthcare Revenue (US$ Million) and Gross Margin (2021-2026)

Table 62. Philips Healthcare Revenue Proportion by Product in 2025

Table 63. Philips Healthcare Revenue Proportion by Application in 2025

Table 64. Philips Healthcare Revenue Proportion by Geographic Area in 2025

Table 65. Philips Healthcare Lung Cancer Screening Software SWOT Analysis

Table 66. Philips Healthcare Recent Developments

Table 67. Canon Medical Systems Corporation Information

Table 68. Canon Medical Systems Description and Major Businesses

Table 69. Canon Medical Systems Product Features and Attributes

Table 70. Canon Medical Systems Revenue (US$ Million) and Gross Margin (2021-2026)

Table 71. Canon Medical Systems Revenue Proportion by Product in 2025

Table 72. Canon Medical Systems Revenue Proportion by Application in 2025

Table 73. Canon Medical Systems Revenue Proportion by Geographic Area in 2025

Table 74. Canon Medical Systems Lung Cancer Screening Software SWOT Analysis

Table 75. Canon Medical Systems Recent Developments

Table 76. United Imaging Healthcare Corporation Information

Table 77. United Imaging Healthcare Description and Major Businesses

Table 78. United Imaging Healthcare Product Features and Attributes

Table 79. United Imaging Healthcare Revenue (US$ Million) and Gross Margin (2021-2026)

Table 80. United Imaging Healthcare Revenue Proportion by Product in 2025

Table 81. United Imaging Healthcare Revenue Proportion by Application in 2025

Table 82. United Imaging Healthcare Revenue Proportion by Geographic Area in 2025

Table 83. United Imaging Healthcare Lung Cancer Screening Software SWOT Analysis

Table 84. United Imaging Healthcare Recent Developments

Table 85. InferVision Corporation Information

Table 86. InferVision Description and Major Businesses

Table 87. InferVision Product Features and Attributes

Table 88. InferVision Revenue (US$ Million) and Gross Margin (2021-2026)

Table 89. InferVision Recent Developments

Table 90. Airdoc Corporation Information

Table 91. Airdoc Description and Major Businesses

Table 92. Airdoc Product Features and Attributes

Table 93. Airdoc Revenue (US$ Million) and Gross Margin (2021-2026)

Table 94. Airdoc Recent Developments

Table 95. VUNO Corporation Information

Table 96. VUNO Description and Major Businesses

Table 97. VUNO Product Features and Attributes

Table 98. VUNO Revenue (US$ Million) and Gross Margin (2021-2026)

Table 99. VUNO Recent Developments

Table 100. Lunit Corporation Information

Table 101. Lunit Description and Major Businesses

Table 102. Lunit Product Features and Attributes

Table 103. Lunit Revenue (US$ Million) and Gross Margin (2021-2026)

Table 104. Lunit Recent Developments

Table 105. Qure.ai Corporation Information

Table 106. Qure.ai Description and Major Businesses

Table 107. Qure.ai Product Features and Attributes

Table 108. Qure.ai Revenue (US$ Million) and Gross Margin (2021-2026)

Table 109. Qure.ai Recent Developments

Table 110. Riverain Technologies Corporation Information

Table 111. Riverain Technologies Description and Major Businesses

Table 112. Riverain Technologies Product Features and Attributes

Table 113. Riverain Technologies Revenue (US$ Million) and Gross Margin (2021-2026)

Table 114. Riverain Technologies Recent Developments

Table 115. Zebra Medical Vision Corporation Information

Table 116. Zebra Medical Vision Description and Major Businesses

Table 117. Zebra Medical Vision Product Features and Attributes

Table 118. Zebra Medical Vision Revenue (US$ Million) and Gross Margin (2021-2026)

Table 119. Zebra Medical Vision Recent Developments

Table 120. Arterys Corporation Information

Table 121. Arterys Description and Major Businesses

Table 122. Arterys Product Features and Attributes

Table 123. Arterys Revenue (US$ Million) and Gross Margin (2021-2026)

Table 124. Arterys Recent Developments

Table 125. Deepwise Corporation Information

Table 126. Deepwise Description and Major Businesses

Table 127. Deepwise Product Features and Attributes

Table 128. Deepwise Revenue (US$ Million) and Gross Margin (2021-2026)

Table 129. Deepwise Recent Developments

Table 130. EverFortune AI Corporation Information

Table 131. EverFortune AI Description and Major Businesses

Table 132. EverFortune AI Product Features and Attributes

Table 133. EverFortune AI Revenue (US$ Million) and Gross Margin (2021-2026)

Table 134. EverFortune AI Recent Developments

Table 135. Technologies, Platforms and Infrastructure

Table 136. Distributors List

Table 137. Market Trends and Market Evolution

Table 138. Market Drivers and Opportunities

Table 139. Market Challenges, Risks, and Restraints

Table 140. Research Programs/Design for This Report

Table 141. Key Data Information from Secondary Sources

Table 142. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Lung Cancer Screening Software Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 2. Cloud-Based Product Picture

Figure 3. Web-Based Product Picture

Figure 4. Global Lung Cancer Screening Software Market Size Growth Rate by Screening Technologies, 2021 vs 2025 vs 2032 (US$ Million)

Figure 5. Nodule Detection Product Picture

Figure 6. Nodule Analysis Product Picture

Figure 7. Full-Process Screening Product Picture

Figure 8. Predictive Assessment Product Picture

Figure 9. Global Lung Cancer Screening Software Market Size Growth Rate by System Integration Level, 2021 vs 2025 vs 2032 (US$ Million)

Figure 10. Standalone AI Software Product Picture

Figure 11. PACS/RIS Integrated Plugin Product Picture

Figure 12. Built-in Solution for Imaging Equipment Product Picture

Figure 13. Regional Screening Platform System Product Picture

Figure 14. Global Lung Cancer Screening Software Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Figure 15. Hospitals

Figure 16. Medical Examination Institutions

Figure 17. Public Health Screening

Figure 18. Others

Figure 19. Lung Cancer Screening Software Report Years Considered

Figure 20. Global Lung Cancer Screening Software Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 21. Global Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 22. Global Lung Cancer Screening Software Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Figure 23. Global Lung Cancer Screening Software Revenue-Based Market Share by Region (2021-2032)

Figure 24. Global Lung Cancer Screening Software Revenue-Based Market Share Ranking (2025)

Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)

Figure 26. Cloud-Based Revenue-Based Market Share by Player in 2025

Figure 27. Web-Based Revenue-Based Market Share by Player in 2025

Figure 28. Global Lung Cancer Screening Software Revenue-Based Market Share by Type (2021-2032)

Figure 29. Global Lung Cancer Screening Software Revenue-Based Market Share by Screening Technologies (2021-2032)

Figure 30. Global Lung Cancer Screening Software Revenue-Based Market Share by System Integration Level (2021-2032)

Figure 31. Global Lung Cancer Screening Software Revenue-Based Market Share by Application (2021-2032)

Figure 32. North America Lung Cancer Screening Software Revenue YoY (US$ Million), 2021-2032

Figure 33. North America Top 5 Players Lung Cancer Screening Software Revenue (US$ Million) in 2025

Figure 34. North America Lung Cancer Screening Software Revenue (US$ Million) by Application (2021-2032)

Figure 35. US Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 36. Canada Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 37. Mexico Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 38. Europe Lung Cancer Screening Software Revenue YoY (US$ Million), 2021-2032

Figure 39. Europe Top 5 Players Lung Cancer Screening Software Revenue (US$ Million) in 2025

Figure 40. Europe Lung Cancer Screening Software Revenue (US$ Million) by Application (2021-2032)

Figure 41. Germany Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 42. France Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 43. U.K. Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 44. Italy Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 45. Russia Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 46. Asia-Pacific Lung Cancer Screening Software Revenue YoY (US$ Million), 2021-2032

Figure 47. Asia-Pacific Top 8 Players Lung Cancer Screening Software Revenue (US$ Million) in 2025

Figure 48. Asia-Pacific Lung Cancer Screening Software Revenue (US$ Million) by Application (2021-2032)

Figure 49. Indonesia Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 50. Japan Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 51. South Korea Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 52. Australia Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 53. India Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 54. Indonesia Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 55. Vietnam Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 56. Malaysia Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 57. Philippines Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 58. Singapore Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 59. Central and South America Lung Cancer Screening Software Revenue YoY (US$ Million), 2021-2032

Figure 60. Central and South America Top 5 Players Lung Cancer Screening Software Revenue (US$ Million) in 2025

Figure 61. Central and South America Lung Cancer Screening Software Revenue (US$ Million) by Application (2021-2032)

Figure 62. Brazil Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 63. Argentina Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 64. Middle East and Africa Lung Cancer Screening Software Revenue YoY (US$ Million), 2021-2032

Figure 65. Middle East and Africa Top 5 Players Lung Cancer Screening Software Revenue (US$ Million) in 2025

Figure 66. Middle East and Africa Lung Cancer Screening Software Revenue (US$ Million) by Application (2021-2032)

Figure 67. GCC Countries Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 68. Israel Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 69. Egypt Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 70. South Africa Lung Cancer Screening Software Revenue (US$ Million), 2021-2032

Figure 71. Lung Cancer Screening Software Value Chain Mapping

Figure 72. Channels of Distribution (Direct Vs Distribution)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Lung Cancer Screening Software in 2026? zhanKai

The global market size of Lung Cancer Screening Software in 2026 was 2013 Million USD.

Which companies rank high in the global Lung Cancer Screening Software market? shouQi

What is the annual compound growth rate of the global Lung Cancer Screening Software market size from 2026 to 2032? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of Lung Cancer Screening Software in 2032? shouQi

Related Reports

Global Lung Cancer Screening Software Market Research Report 2026
The global Lung Cancer Screening Software market was valued at US$ 1706 million in 2025 and is anticipated to reach US$ 5434 million by 2032, at a CAGR of 18.0% from 2026 to 2032.
Published Date: 2026-01-14
Pages: 115
USD 2900.00
(Single User License)
Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Lung Cancer Screening Software was estimated to be worth US$ 1706 million in 2025 and is projected to reach US$ 5434 million, growing at a CAGR of 18.0% from 2026 to 2032.
Published Date: 2026-01-14
Pages: 117
USD 3950.00
(Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Lung Cancer Screening Software market size was US$ 1706 million in 2025 and is forecast to reach a readjusted size of US$ 5434 million by 2032 with a CAGR of 18.0% during the forecast period 2026-2032.
Published Date: 2026-01-14
Pages: 98
USD 4250.00
(Single User License)
Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Lung Cancer Screening Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-10-23
Pages: 126
USD 4900.00
(Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Lung Cancer Screening Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-20
Pages: 77
USD 4250.00
(Single User License)
Lung Cancer Screening Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-20
Pages: 100
USD 3950.00
(Single User License)
Global Lung Cancer Screening Software Market Research Report 2025
The global market for Lung Cancer Screening Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-20
Pages: 74
USD 2900.00
(Single User License)
Global Lung Cancer Screening Software Market Insights, Forecast to 2030
Market Analysis and Insights: Global Lung Cancer Screening Software Market
Published Date: 2024-04-07
Pages: 89
USD 4900.00
(Single User License)
Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-02-19
Pages: 92
USD 3950.00
(Single User License)
Global Lung Cancer Screening Software Market Research Report 2024
The global Lung Cancer Screening Software market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-01-11
Pages: 79
USD 2900.00
(Single User License)

Global Lung Cancer Screening Software Market Research Report 2026
The global Lung Cancer Screening Software market was valued at US$ 1706 million in 2025 and is anticipated to reach US$ 5434 million by 2032, at a CAGR of 18.0% from 2026 to 2032.
Published: 2026-01-14
Pages: 115
USD 2900.00 (Single User License)
Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Lung Cancer Screening Software was estimated to be worth US$ 1706 million in 2025 and is projected to reach US$ 5434 million, growing at a CAGR of 18.0% from 2026 to 2032.
Published: 2026-01-14
Pages: 117
USD 3950.00 (Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Lung Cancer Screening Software market size was US$ 1706 million in 2025 and is forecast to reach a readjusted size of US$ 5434 million by 2032 with a CAGR of 18.0% during the forecast period 2026-2032.
Published: 2026-01-14
Pages: 98
USD 4250.00 (Single User License)
Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Lung Cancer Screening Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-10-23
Pages: 126
USD 4900.00 (Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Lung Cancer Screening Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-20
Pages: 77
USD 4250.00 (Single User License)
Lung Cancer Screening Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-20
Pages: 100
USD 3950.00 (Single User License)
Global Lung Cancer Screening Software Market Research Report 2025
The global market for Lung Cancer Screening Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-20
Pages: 74
USD 2900.00 (Single User License)
Global Lung Cancer Screening Software Market Insights, Forecast to 2030
Market Analysis and Insights: Global Lung Cancer Screening Software Market
Published: 2024-04-07
Pages: 89
USD 4900.00 (Single User License)
Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published: 2024-02-19
Pages: 92
USD 3950.00 (Single User License)
Global Lung Cancer Screening Software Market Research Report 2024
The global Lung Cancer Screening Software market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-01-11
Pages: 79
USD 2900.00 (Single User License)